You are here: Industry Insights > COVID-19

News List

Zydus Cadila files IND application for ZYIL1, NLRP3 inflammasome inhibitor expresspharma
November 05, 2020
Zydus announced that it has filed the IND application of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. Following up on its initiatives to fight COVID 19 with diagnostics, vaccines and therapeutics, the company is now focussing on ...
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy americanpharmaceuticalreview
November 05, 2020
Agenus announced the dosing of the first COVID-19 patient with agenT-797, an allogeneic cell therapy, through its subsidiary, AgenTus Therapeutics. The trial is being led by Dr. Koen van Besien at ...
Oxford BioDynamics enters strategic partnership with Boca Biolistics pharmatimes
November 05, 2020
Oxford BioDynamics has entered a strategic partnership with US-based biorepository, reference lab and contract research organisation Boca Biolistics.
UK regulator initiates rolling review of AstraZeneca’s vaccine for Covid-19 pharmaceutical-technology
November 04, 2020
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has initiated the accelerated rolling review of AstraZeneca’s potential vaccine to treat Covid-19.
Covid-19 cases increase ahead of US presidential election pharmaceutical-technology
November 04, 2020
Ahead of the US presidential election, Midwestern states in the country are experiencing a record number of Covid-19-related hospitalisations indicating an exponential surge in cases.
Experts seek data on remdesivir and COVID-19 treatment-related products expresspharma
November 04, 2020
Recently, Dr Reddy’s Laboratories’ plea to change the regulatory approval status of remdesivir injection, COVID-19 treatment drug, from restricted emergency use to full marketing authorisation was rejected by COVID-19 subject expert committee (SEC) of ...
CEPI extends partnership with Clover Biopharma to fund COVID-19 vaccine candidate expresspharma
November 04, 2020
CEPI to fund the development of Clover’s protein-based S-Trimer vaccine candidate through to licensure, including a global pivotal Phase 2/3 efficacy clinical study beginning before the end of 2020.
New study assessing antibiotics for COVID-19 sepsis pharmatimes
November 04, 2020
Researchers from an NIHR-funded study are looking at how to improve the use of antibiotics for patients with COVID-19 who are at risk of developing sepsis and thus organ failure and death.
RevImmune Advances New COVID-19 Immunotherapy americanpharmaceuticalreview
November 04, 2020
RevImmune announced its "ILIAD-7" international randomized controlled Phase 2 trial in patients critically ill with COVID-19, is now enrolling patients at five sites in the U.S.
Humanigen announces first patient dosed in NIH ACTIV-5/Big Effect trial evaluating lenzilumab for Covid-19 pharmaceutical-business-review
November 04, 2020
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that the first patient has been dosed at the Emory University School of Medicine in Atlanta, Georgia as...